

# Non-Alcoholic Steatohepatitis Therapeutic and Drug Pipeline Review H2

*Non-Alcoholic Steatohepatitis Therapeutic Pipeline Market Review, H2 2017*

PUNE, INDIA, March 17, 2017  
/EINPresswire.com/ -- [Non-Alcoholic Steatohepatitis](#) - Pipeline Review, H1 2017

## Summary

Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason,

general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.



**WISE GUY**  
REPORTS

AKASH ANAND  
ASST.MANAGER - BUSINESS DEVELOPMENT

sales@wiseguyreports.com  
Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

<https://www.linkedin.com/company/4828928>  
<http://twitter.com/WiseGuyReports>  
<http://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/1056686-non-alcoholic-steatohepatitis-pipeline-review-h1-2017>

## Report Highlights

This report provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 26, 19, 3, 66, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

## Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic

## Steatohepatitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)

## Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Table of Content: Key Points

Table of Contents 2

Introduction 6

Non-Alcoholic Steatohepatitis - Overview 7

Non-Alcoholic Steatohepatitis - Therapeutics Development 8

Non-Alcoholic Steatohepatitis - Therapeutics Assessment 26

Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 41

Non-Alcoholic Steatohepatitis - Drug Profiles 83

Non-Alcoholic Steatohepatitis - Dormant Projects 372

Non-Alcoholic Steatohepatitis - Discontinued Products 374

Non-Alcoholic Steatohepatitis - Product Development Milestones 375

...Continued

ACCESS REPORT @ <https://www.wiseguyreports.com/sample-request/1056686-non-alcoholic-steatohepatitis-pipeline-review-h1-2017>

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.